Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

NANOPARTICLE (NP)-ENHANCED EXPRESSION OF AQUAPORIN-4 CHANNELS AND WATER TRANSPORT IN HUMAN ASTROCYTES

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Publication Date:
    December 26, 2024
  • Additional Information
    • Document Number:
      20240424017
    • Appl. No:
      18/750592
    • Application Filed:
      June 21, 2024
    • Abstract:
      A method of inducing expression of aquaporin-4 by providing a bioconjugate having a quantum dot bound to human erythropoietin and contacting human astrocytes with the bioconjugate, which induces expression of aquaporin-4. A composition having a bioconjugate having a quantum dot bound to human erythropoietin. A method of providing a quantum dot and forming a bioconjugate by depositing human erythropoietin onto the surface of the quantum dot.
    • Assignees:
      The Government of the United States of America, as represented by the Secretary of the Navy (Arlington, VA, US)
    • Claim:
      1. A method of inducing expression of aquaporin-4, the method comprising: providing a bioconjugate comprising a quantum dot bound to human erythropoietin; and contacting human astrocytes with the bioconjugate, thereby inducing expression of aquaporin-4 by the human astrocytes.
    • Claim:
      2. The method of claim 1, wherein the quantum dot comprises a cadmium selenide core; an inner cadmium sulfide shell in contact with the cadmium selenide core; and an outer zinc sulfide shell in contact the inner cadmium sulfide shell.
    • Claim:
      3. The method of claim 1, wherein the quantum dot is a gold nanoparticle, a non-gold metal nanoparticle, or a liposome.
    • Claim:
      4. The method of claim 1, wherein the quantum dot comprises a solubilizing ligand.
    • Claim:
      5. The method of claim 4, wherein the solubilizing ligand is N-(2-carboxyethyl)-N-[2-[(6,8-dimercapto-1-oxooctyl)amino]ethyl]-β-alanine.
    • Claim:
      6. The method of claim 1, wherein the human erythropoietin comprises a poly-histidine tail.
    • Claim:
      7. The method of claim 1, wherein the quantum dot has from 2 to 40 molecules of the human erythropoietin deposited thereon.
    • Claim:
      8. A composition comprising: a bioconjugate comprising a quantum dot bound to human erythropoietin.
    • Claim:
      9. The composition of claim 8, wherein the quantum dot comprises: a cadmium selenide core; an inner cadmium sulfide shell in contact with the cadmium selenide core; and an outer zinc sulfide shell in contact the inner cadmium sulfide shell.
    • Claim:
      10. The composition of claim 8, wherein the quantum dot is a gold nanoparticle, a non-gold metal nanoparticle, or a liposome.
    • Claim:
      11. The composition of claim 8, wherein the quantum dot comprises a solubilizing ligand.
    • Claim:
      12. The composition of claim 11, wherein the solubilizing ligand is N-(2-carboxyethyl)-N-[2-[(6,8-dimercapto-1-oxooctyl)amino]ethyl]-β-alanine.
    • Claim:
      13. The composition of claim 8, wherein the human erythropoietin comprises a poly-histidine tail.
    • Claim:
      14. The composition of claim 8, wherein the quantum dot has from 2 to 40 molecules of the human erythropoietin deposited thereon.
    • Claim:
      15. A method comprising: providing a quantum dot; and forming a bioconjugate by depositing human erythropoietin onto the surface of the quantum dot.
    • Claim:
      16. The method of claim 15, wherein the quantum dot comprises: a cadmium selenide core; an inner cadmium sulfide shell in contact with the cadmium selenide core; and an outer zinc sulfide shell in contact the inner cadmium sulfide shell.
    • Claim:
      17. The method of claim 15, wherein the quantum dot is a gold nanoparticle, a non-gold metal nanoparticle, or a liposome.
    • Claim:
      18. The method of claim 15, wherein the quantum dot comprises a solubilizing ligand.
    • Claim:
      19. The method of claim 18, wherein the solubilizing ligand is N-(2-carboxyethyl)-N-[2-[(6,8-dimercapto-1-oxooctyl)amino]ethyl]-β-alanine.
    • Claim:
      20. The method of claim 15, wherein the human erythropoietin comprises a poly-histidine tail.
    • Claim:
      21. The method of claim 15, wherein from 2 to 40 molecules of the human erythropoietin are deposited onto the quantum dot.
    • Current International Class:
      61; 61; 61; 61; 61
    • Accession Number:
      edspap.20240424017